Evaluation of tamoxifen in persistent or recurrent nonsquamous cell carcinoma of the cervix: A Gynecologic Oncology Group study

International Journal of Gynecological Cancer

Volumn 14, Issue 5, 2004, Pages 871-874

  Bigler, L R ^a   Thigpen, J Tate ^a   Blessing, J A ^b   Fiorica, J ^c   Monk, B J ^d  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Squamous cell carcinoma; Tamoxifen citrate

Indexed keywords

TAMOXIFEN CITRATE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; EVALUATION; FEMALE; GASTROINTESTINAL SYMPTOM; HOT FLUSH; HUMAN; HUMAN TISSUE; KIDNEY DISEASE; LEUKOPENIA; MULTICENTER STUDY; NEUROPATHY; NEUTROPENIA; ONCOLOGY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; REGISTER; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TAMOXIFEN; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 4544337336     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1048-891X.2004.14523.x     Document Type: Article

References (23)

1. Howley P. Role of human papillomaviruses in human cancer. Cancer Res 1991;51:5019-22.
2. zur Hausen H. Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 1991;184:9-13.
3. Farthing AJ, Vousden K. Functions of human papillomavirus E6 and E7 oncoproteins. Trends Microbiol 1994;2:170-4.
4. Hildesheim A, Reeves WC, Brinton LA et al. Association of oral contraceptive use and human papillomaviruses in invasive cervical cancers. Int J Cancer 1990;45:860-4.
5. Herrero R, Brinton LA, Reeves WC et al. Injectable contraceptives and risk of invasive cervical cancer: evidence of an association. Int J Cancer 1990;46:5-7.
6. Brinton L, Reeves WC, Brenes MM et al. Parity as a risk factor for cervical cancer. Am J Epidemiol 1989;130:486-96.
7. Pater MM, Mittal R, Pater A. Role of steroid hormones in potentiating transformation of cervical cells by human papillomaviruses. Trends Microbiol 1994;2:230-5.
8. Chin MT, Broker TR, Chow LT. Identification of a novel constitutive enhancer element and an associated binding protein: implications for human papillomavirus type 11 enhancer regulation. J Virol 1989;63:2967-76.
9. Chan WK, Klock G, Bernard HU. Progesterone and glucocorticoid response elements occur in the long control regions of several human papilloma viruses involved in anogenital neoplasia. J Virol 1989;63:3261-9.
10. Blessing JA. Design, analysis and interpretation of chemotherapy trials in gynecologic cancer. In: Deppe G, ed. Chemotherapy of Gynecologic Cancer. New York: Alan R. Liss, 1990.
11. Bloss J, Thigpen JT. Chemotherapy of gynecologic cancers. In: Perry M, ed. The Chemotherapy Source Book, 3rd edn. Philadelphia: Lippincott Williams & Wilkins; 2001:732-60.
12. Pater MM, Hughes GA, Hyslop DE, Nakshatri H, Pater A. Glucocorticoid-dependent oncogenic transformation by type 16 but not type 11 human papillomavirus DNA. Nature 1988;335:832-5.
13. Crook T, Storey A, Almond N, Osborn K, Crawford L. Human papillomavirus type 16 cooperates with activated ras and fos oncogenes in the hormone-dependent transformation of primary mouse cells. Proc Natl Acad Sci 1988;85:8820-4.
14. Pater MM, Pater A. RU486 inhibits glucocorticoid hormone-dependent oncogenesis by human papillomavirus type 16 DNA. Virology 1991;183:799-802.
15. Schlegel R, Phelps WC, Zhang YL, Barbosa M. Quantitative keratinocyte assay detects two biological activities of human papillomavirus DNA and identifies viral types associated with cervical carcinoma. EMBO J 1988;7:3181-7.
16. Mittal R, Tsutsumi K, Pater A, Pater MM. Human papillomavirus type 16 expression in cervical keratinocytes: role of progesterone and glucocorticoid hormones. Obstet Gynecol 1993;81:5-12.
17. Gorodeski GI, Eckert RL, Utian WH, Sheean L, Rorke EA. Cultured human ectocervical epithelial cell differentiation is regulated by the combined direct actions of sex steroids, glucocorticoids and retinoids. J Clin Endocrinol Metab 1990;70:1624-30.
18. Mittal R, Pater A, Pater MM. Multiple human papillomavirus type 16 glucocorticoid response elements functional for transformation, transient expression and DNA-protein interactions. J Virol 1993;67:5656-9.
19. Pater MM, Nakshatri H, Kisaka C, Pater A. The first 124 nucleotides of the E7 coding sequences of HPV 16 can render the HPV 11 genome transformation competent. Virology 1992;186:348-51.
20. Hwang JY, Lin BY, Tang FM, Yu WC. Tamoxifen stimulates human papillomavirus type 16 gene expression and cell proliferation in a cervical cell line. Cancer Res 1992;52:6848-52.
21. Vargas Roig LM, Lotfi H, Olcese JE, Lo Castro G, Ciocca DR. Effects of short-term tamoxifen administration in patients with invasive cervical carcinoma. Anticancer Res 1993;13:2457-63.
22. von Knebel Doeberitz M, Bauknecht T, Bartsch D, zur Hausen H. Influence of chromosomal integration on glucocorticoid-regulated transcription of growth-stimulating papillomavirus genes E6 and E7 in cervical carcinoma cells. Proc Natl Acad Sci 1991;88:1411-5.
23. Ragaz J, Coldman A. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes. J Clin Oncol 1998;16:2018-24.